RT Journal Article
SR Electronic
T1 Cumulative Active and Recovery Rates Based Criterion for Gradual Lockdown Exit: A Global Observation of SARS Cov-2 Management
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20123364
DO 10.1101/2020.06.05.20123364
A1 Dhananjay V Raje
A1 Abhay Bajaj
A1 Moumita Chakraborty
A1 Hemant J Purohit
YR 2020
UL http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123364.abstract
AB On March 11, 2020 the World Health Organization (WHO) had declared SARS-CoV-2 pandemic; and at present there are over 6 million cases across the globe. Based on the interim guidelines of WHO, most of the countries opted for social distancing with lockdown as the only way to control the pandemic. This led to ‘Manufacturing’ shut down, which acted as a spanner in the wheel for international supply chain leading to pressure on governments to review the protocols of the lockdown. We studied epidemiological parameters for 18 countries and obtained crossover time point referring to cumulative case active and case recovery rates and the time point for the peak positive confirmation rate in a time window of 92 days; and linked with the respective governmental decisions. For countries awaiting crossover, time series non-linear models could be used for predicting the crossover point. A sample study was carried out for India. The median time for reaching crossover for 12 countries was 37 days, while peak positive confirmation rate was 30 days after their first intervention. These countries enforced strict lockdown regulations and have shown constant improvement in their recovery rate even after crossover time point. A phase wise relaxation of lockdown is evident after crossover point in most of these countries. The crossover time point with the subsequent increasing recovery rate can be a strategy for lockdown relaxation as evident from the experiences of few countries. Also, we propose a criterion based on 28 cumulative recovery and fatality rate for micro-management of lockdown.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialno clinical trial data reportedFunding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study is exempted as no clinical data is used or obtainedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available in public domain. https://www.gisaid.org/epiflu-applications/next-hcov-19-app/ https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19stat.shinyapps.io/covid19status/